Valbenazine
| Clinical data | |
|---|---|
| Trade names | Ingrezza |
| Other names | NBI-98854 |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a617023 |
| License data |
|
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Protein binding | >99% |
| Metabolism | Activation by hydrolysis, deactivation by CYP3A, CYP2D6 |
| Metabolites | [+]-α-Dihydrotetrabenazine (active metabolite) |
| Elimination half-life | 15–22 hrs |
| Excretion | 60% urine, 30% faeces |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.236.234 |
| Chemical and physical data | |
| Formula | C24H38N2O4 |
| Molar mass | 418.578 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Valbenazine, sold under the brand name Ingrezza, is a medication used to treat tardive dyskinesia. It acts as a vesicular monoamine transporter 2 (VMAT2) inhibitor.